Results

Scientific results are shown on posters at congresses

Generally, RABBIT shows biologic DMARDs to be effective, safe and well tolerated in daily rheumatologic care. Used by experienced rheumatologists, they are a safe treatment option for patients with rheumatoid arthritis, who do not respond adequately to non-biologic DMARDs.

In practice, biologic DMARDs are not prescribed until non-biologic DMARDs fail or are not tolerated. That means that patients for whom biologic DMARDs are indicated differ systematically from patients who are treated with non-biologic DMARDs. Therefore, highly sophisticated statistical methods are required to compare patients on biologic and non-biologic DMARDs.

Here, we will give a short insight into our published results: Original publications

Eingeschlossene Patienten: 21.393 (Stand 1. August 2022) 
Amgevita® (Adalimumab)153
Benepali® (Etanercept)940
Cimzia® (Certolizumab)986
Enbrel® (Etanercept)2868
Erelzi® (Etanercept)406
Flixabi® (Infliximab)9
Hulio® (Adalimumab)136
Humira® (Adalimumab)2903
Hyrimoz® (Adalimumab)135
Idacio® (Adalimumab)41
Imraldi® (Adalimumab)150
Inflectra™ (Infliximab)16
Jyseleca® (Filgotinib)63
Kevzara® (Sarilumab)178
Kineret® (Anakinra)89
MabThera® (Rituximab)1459
Nepexto® (Etanercept)25
Olumiant® (Baricitinib)496
Orencia® (Abatacept)912
Remicade® (Infliximab)762
Remsima® (Infliximab)12
Rinvoq® (Upadacitinib)241
Rixathon® (Rituximab)18
RoActemra® (Tocilizumab)1335
Ruxience® (Rituximab)1
Simponi® (Golimumab)453
Xeljanz® (Tofacitinib)387
Zessly® (Infliximab)2
Kontrollen6217